Investor Presentaiton

ENHERTU® Performance in Each Region (Japan, ASCA) Global product sales: FY2023 Q1 results 81.7 Bn JPY (YOY +50.4 Bn JPY) FY2023 forecast 320.0 Bn JPY (YOY +112.5 Bn JPY) >ENHERTU trastuzumab deruxtecan Japan Product sales: FY2023Q1 results 4.4 Bn JPY FY2023 forecast 19.9 Bn JPY Indication: HER2+ mBC 2L+, HER2 low mBC (post-chemo), HER2+ MGC 3L 4.4 Bn JPY 2.4 Bn JPY 2.2 Bn JPY Market share status 8.0 Bn JPY FY2022 Q1 FY2023 Q1 FY2022 Q1 FY2023 Q1 Japan ASCA ASCA HER2+ MBC 2L: Achieved No.1 new patient share HER2 low mBC: Steady uptake in capturing new patient share HER2+ MGC 3L: Maintaining No.1 new patient share Product sales: FY2023Q1 results 8.0 Bn JPY FY2023 forecast 29.2 Bn JPY Indication: HER2+ mBC 2L+, HER2 low mBC (post-chemo), HER2+ mGC 3L Market share status Sales growing in Brazil, Hong Kong and Taiwan Other progress China: Launched for HER2+ mBC 2L (Jun. 2023), Approved for HER2 low mBC (post-chemo) and started promotion (Jul. 2023) Daiichi-Sankyo 13

View entire presentation